Shanghai Henlius Biotech (SEHK:2696) Advances Pipeline As Fair Value Questions Grow

Shanghai Henlius Biotech (SEHK:2696) has moved into focus after dosing the first patient in an international multicenter phase 1 trial of its nivolumab biosimilar HLX18 for multiple resected solid tumors.

See our latest analysis for Shanghai Henlius Biotech.

Despite the clinical progress, Shanghai Henlius Biotech’s share price has been under pressure in recent months, with a 30 day share price return of down 5.79% and a 90 day share price return of down 28.49%. The 3 year total shareholder return of about 3.7x suggests earlier investors have still seen very large gains overall, which hints that momentum has faded recently even as the long term story remains intact.

If immuno oncology developments like HLX18 interest you, this can be a good moment to look across the sector and review 127 healthcare AI stocks

Shanghai Henlius Biotech’s share price has slipped even as analysts’ estimates and intrinsic value models sit far above the current HK$59.35 level. How far from fair value might the stock really be trading?

Price-to-Earnings of 33.7x: Is It Justified for Shanghai Henlius Biotech?

On traditional metrics, Shanghai Henlius Biotech does not look cheap, with the stock trading on a P/E of 33.7x at a last close of HK$59.35. At the same time, intrinsic value models and analyst targets imply a much higher value. This sets up a clear tension between what the market is paying for each dollar of earnings and what various models suggest those earnings could be worth.

The P/E ratio tells you how much investors are willing to pay today for each unit of current earnings. For a biotech group like Shanghai Henlius Biotech, which is already profitable and reporting net income of HK$827.04m on revenue of HK$6,666.63m, a higher P/E can often reflect expectations for continued product rollout, pipeline progress and the quality of its earnings profile. The company is described as having high quality earnings and a high Return on Equity of 20.9%, which can also support a richer earnings multiple.

However, the current 33.7x P/E is above the estimated fair P/E of 16.9x. It also sits slightly above both the peer average of 33.5x and the Asian biotech industry average of 31.2x. That means the stock is not only priced at a premium to the level the SWS fair ratio indicates the market could move towards over time, it is also trading at a small premium to sector benchmarks despite forecasts that earnings and revenue growth will be below 20% a year and slightly slower than the wider Hong Kong market.

Explore the SWS fair ratio for Shanghai Henlius Biotech

Result: Preferred multiple of Price-to-Earnings of 33.7x (OVERVALUED)

However, Shanghai Henlius Biotech’s premium P/E and recent share price weakness could quickly unwind if pipeline trials disappoint or pricing pressures affect key biologic products.

Find out about the key risks to this Shanghai Henlius Biotech narrative.

Another View: What Does the SWS DCF Model Say About Shanghai Henlius Biotech?

While the current P/E of 33.7x suggests Shanghai Henlius Biotech is expensive relative to its earnings, the SWS DCF model points the other way. At HK$59.35, the stock is described as trading below an estimated future cash flow value of HK$192.31, which frames the current price as a large discount rather than a premium.

That gap between earnings based valuation and cash flow based valuation raises a simple question for you as an investor: which lens do you trust more when the story from each is this different?

Look into how the SWS DCF model arrives at its fair value.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Shanghai Henlius Biotech for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 232 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

With Shanghai Henlius Biotech presenting both potential risks and rewards, take a moment to look through the numbers yourself and decide how comfortable you feel with the story. To review both sides in one place, see the 4 key rewards and 1 important warning sign

Looking for more investment ideas beyond Shanghai Henlius Biotech?

If Shanghai Henlius Biotech has sharpened your interest, now is a smart time to broaden your watchlist with other focused ideas that match your risk and return preferences.

• Target stability first by checking companies in the 292 resilient stocks with low risk scores that may better fit a cautious approach.
• Hunt for value by scanning the 232 high quality undervalued stocks that pair quality fundamentals with potentially attractive pricing.
• Strengthen your income plan by reviewing the 460 dividend fortresses that concentrate on higher yielding dividend payers.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com